Lifecore Biomedical Inc (NAS:LFCR)

Q1 2026 Lifecore Biomedical Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: $6.62 (-2.22%)

Transcript 10-Q8-K

Key Points

Positve

Lifecore Biomedical Inc (LFCR) reported a 26% increase in revenue compared to the prior year period, demonstrating strong financial performance.
The company achieved significant milestones in expanding its commercial business and advancing its late-stage pipeline programs.
Lifecore Biomedical Inc (LFCR) successfully conducted five customer audits, including a due diligence audit with a large multinational pharmaceutical company, all of which were positive.
The company signed two new business wins during the third quarter and made substantial progress on two additional projects signed after the quarter ended.
Lifecore Biomedical Inc (LFCR) has implemented a revamped commercial strategy that has expanded its target market and is already delivering impressive results.

Negative

Despite improvements, Lifecore Biomedical Inc (LFCR) recorded a net loss of $10 million for the quarter.
The company experienced a decrease in CDMO gross profit due to lower development revenues and a decrease in aseptic gross profit.
Lifecore Biomedical Inc (LFCR) is still dealing with legacy matters, which have impacted its financial performance.
The commercial site transfer for a large pharma company is expected to take 24 to 30 months, indicating a long timeline before realizing potential revenue.
The company faces challenges in maintaining its adjusted EBITDA margins, with a target of 25% still in progress.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LFCR.OQ - Lifecore Biomedical Inc
Q1 2026 Lifecore Biomedical Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and thank you for joining Life Corp's Q3 2025 earnings call for the three months ended September 30th, 2025. During the call, all participants will be in a listen-only mode. Now, I would like to turn the call over to Stephanie Diaz, Manager of Investor relations for LifeCorp.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and thank you for joining us today to discuss Life Corps Biomedical's third quarter 2025 earnings results. The three months ended September 30th, 2025. As we announced in August, the company has changed its fiscal year end to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.